Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Design and analysis of a clinical trial using previous trials as historical control.

Schoenfeld DA, Finkelstein DM, Macklin E, Zach N, Ennist DL, Taylor AA, Atassi N; Pooled Resource Open-Access ALS Clinical Trials Consortium.

Clin Trials. 2019 Oct;16(5):531-538. doi: 10.1177/1740774519858914. Epub 2019 Jul 1.

PMID:
31256630
2.

Are rare cancer survivors at elevated risk of subsequent new cancers?

Finkelstein DM, Horick NK, Ramchandani R, Boyd KL, Rana HQ, Bychkovsky BL.

BMC Cancer. 2019 Feb 21;19(1):166. doi: 10.1186/s12885-019-5358-1.

3.

Estimation for an accelerated failure time model with intermediate states as auxiliary information.

Ramchandani R, Finkelstein DM, Schoenfeld DA.

Lifetime Data Anal. 2018 Nov 1. doi: 10.1007/s10985-018-9452-5. [Epub ahead of print]

PMID:
30386969
4.

Physical symptoms in long-term survivors of rare cancer.

Horick NK, Muzikansky A, Gutierrez HL, Boyd KL, Finkelstein DM.

J Cancer Surviv. 2018 Dec;12(6):835-842. doi: 10.1007/s11764-018-0721-9. Epub 2018 Oct 12.

PMID:
30315392
5.

Graphing the Win Ratio and its components over time.

Finkelstein DM, Schoenfeld DA.

Stat Med. 2019 Jan 15;38(1):53-61. doi: 10.1002/sim.7895. Epub 2018 Sep 11.

PMID:
30206956
6.

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.

Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O.

Front Oncol. 2018 May 22;8:156. doi: 10.3389/fonc.2018.00156. eCollection 2018. Review.

7.

Informatively clustering longitudinal microarrays using binary or survival outcome data.

Hsu JJ, Finkelstein DM, Schoenfeld DA.

Commun Stat Case Stud Data Anal Appl. 2018;4(1):18-27. doi: 10.1080/23737484.2018.1455542. Epub 2018 Apr 9.

8.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

9.

Promoting Children's Physical Activity in Low-Income Communities in Colorado: What Are the Barriers and Opportunities?

Finkelstein DM, Petersen DM, Schottenfeld LS.

Prev Chronic Dis. 2017 Dec 14;14:E134. doi: 10.5888/pcd14.170111.

10.

A pilot investigation of an iOS-based app for toilet training children with autism spectrum disorder.

Mruzek DW, McAleavey S, Loring WA, Butter E, Smith T, McDonnell E, Levato L, Aponte C, Travis RP, Aiello RE, Taylor CM, Wilkins JW, Corbett-Dick P, Finkelstein DM, York AM, Zanibbi K.

Autism. 2019 Feb;23(2):359-370. doi: 10.1177/1362361317741741. Epub 2017 Dec 7.

PMID:
29212345
11.

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, Lu KH.

Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.

12.

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.

Chavarri-Guerra Y, St Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE.

Breast. 2017 Feb;31:197-201. doi: 10.1016/j.breast.2016.11.014. Epub 2016 Nov 25.

13.

Physical and psychological health in rare cancer survivors.

Horick NK, Manful A, Lowery J, Domchek S, Moorman P, Griffin C, Visvanathan K, Isaacs C, Kinney AY, Finkelstein DM.

J Cancer Surviv. 2017 Feb;11(1):158-165. doi: 10.1007/s11764-016-0573-0. Epub 2016 Oct 19.

14.

Assessing survival benefit when treatment delays disease progression.

Schoenfeld DA, Finkelstein DM.

Clin Trials. 2016 Jun;13(3):352-7. doi: 10.1177/1740774515625990. Epub 2016 Feb 22.

15.

Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project.

Patel SG, Ahnen DJ, Kinney AY, Horick N, Finkelstein DM, Hill DA, Lindor NM, MaCrae F, Lowery JT.

Am J Gastroenterol. 2016 Feb;111(2):285-93. doi: 10.1038/ajg.2015.397. Epub 2016 Feb 9.

16.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
17.

Global rank tests for multiple, possibly censored, outcomes.

Ramchandani R, Schoenfeld DA, Finkelstein DM.

Biometrics. 2016 Sep;72(3):926-35. doi: 10.1111/biom.12475. Epub 2016 Jan 26.

18.

A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report.

Reilly-Harrington NA, Shelton RC, Kamali M, Rabideau DJ, Shesler LW, Trivedi MH, McElroy SL, Sylvia LG, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Bobo WV, Deckersbach T, Tohen M, McInnis MG, Kocsis JH, Gold AK, Singh V, Finkelstein DM, Kinrys G, Nierenberg AA.

J Affect Disord. 2016 Mar 1;192:212-8. doi: 10.1016/j.jad.2015.12.036. Epub 2015 Dec 30.

PMID:
26748736
19.

Outcome-Driven Cluster Analysis with Application to Microarray Data.

Hsu JJ, Finkelstein DM, Schoenfeld DA.

PLoS One. 2015 Nov 12;10(11):e0141874. doi: 10.1371/journal.pone.0141874. eCollection 2015.

20.

Evaluating Academic Scientists Collaborating in Team-Based Research: A Proposed Framework.

Mazumdar M, Messinger S, Finkelstein DM, Goldberg JD, Lindsell CJ, Morton SC, Pollock BH, Rahbar MH, Welty LJ, Parker RA; Biostatistics, Epidemiology, and Research Design (BERD) Key Function Committee of the Clinical and Translational Science Awards (CTSA) Consortium.

Acad Med. 2015 Oct;90(10):1302-8. doi: 10.1097/ACM.0000000000000759.

21.

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Breast Cancer Res. 2015 Apr 16;17:56. doi: 10.1186/s13058-015-0568-1.

22.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

23.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
24.

Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK.

J Natl Cancer Inst. 2015 Feb 20;107(4). pii: djv017. doi: 10.1093/jnci/djv017. Print 2015 Apr.

25.

A model-informed rank test for right-censored data with intermediate states.

Ramchandani R, Finkelstein DM, Schoenfeld DA.

Stat Med. 2015 Apr 30;34(9):1454-66. doi: 10.1002/sim.6417. Epub 2015 Jan 13.

26.

Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective.

Chavarri-Guerra Y, St Louis J, Liedke PE, Symecko H, Villarreal-Garza C, Mohar A, Finkelstein DM, Goss PE.

BMC Cancer. 2014 Sep 9;14:658. doi: 10.1186/1471-2407-14-658.

27.

Breast cancer in China.

Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE.

Lancet Oncol. 2014 Jun;15(7):e279-89. doi: 10.1016/S1470-2045(13)70567-9. Review.

PMID:
24872111
28.

Poor Survival for American Indians with Head and Neck Squamous Cell Carcinoma.

Dwojak SM, Finkelstein DM, Emerick KS, Lee JH, Petereit DG, Deschler DG.

Otolaryngol Head Neck Surg. 2014 Aug;151(2):265-71. doi: 10.1177/0194599814533083. Epub 2014 Apr 28.

PMID:
24781656
29.

Long-term risk of medical conditions associated with breast cancer treatment.

Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM.

Breast Cancer Res Treat. 2014 May;145(1):233-43. doi: 10.1007/s10549-014-2928-4. Epub 2014 Apr 3.

30.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE.

J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.

PMID:
24687830
31.

A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network.

Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, Lindor NM, Newcomb PA, Sandler RS, Burke C, Hill DA, Ahnen DJ.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):601-10. doi: 10.1158/1055-9965.EPI-13-1085. Epub 2014 Feb 5.

32.

A joint test for progression and survival with interval-censored data from a cancer clinical trial.

Finkelstein DM, Schoenfeld DA.

Stat Med. 2014 May 30;33(12):1981-9. doi: 10.1002/sim.6096. Epub 2014 Feb 6.

33.

Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study.

Liedke PE, Finkelstein DM, Szymonifka J, Barrios CH, Chavarri-Guerra Y, Bines J, Vasconcelos C, Simon SD, Goss PE.

Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):126-33. doi: 10.1158/1055-9965.EPI-13-0693. Epub 2013 Oct 28.

34.

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Specht MC, Miller CL, Russell TA, Horick N, Skolny MN, O'Toole JA, Jammallo LS, Niemierko A, Sadek BT, Shenouda MN, Finkelstein DM, Smith BL, Taghian AG.

Breast Cancer Res Treat. 2013 Aug;140(3):485-94. doi: 10.1007/s10549-013-2655-2. Epub 2013 Aug 4.

35.

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE.

J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093/jnci/djt146. Epub 2013 Jun 28.

36.

Strategies for developing biostatistics resources in an academic health center.

Welty LJ, Carter RE, Finkelstein DM, Harrell FE Jr, Lindsell CJ, Macaluso M, Mazumdar M, Nietert PJ, Oster RA, Pollock BH, Roberson PK, Ware JH; Biostatistics, Epidemiology, and Research Design Key Function Committee of the Clinical and Translational Science Award Consortium.

Acad Med. 2013 Apr;88(4):454-60. doi: 10.1097/ACM.0b013e31828578ed.

37.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; TEACH investigators.

Lancet Oncol. 2013 Jan;14(1):88-96. doi: 10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.

PMID:
23234763
38.

Breast cancer in Mexico: a growing challenge to health and the health system.

Chávarri-Guerra Y, Villarreal-Garza C, Liedke PE, Knaul F, Mohar A, Finkelstein DM, Goss PE.

Lancet Oncol. 2012 Aug;13(8):e335-43. doi: 10.1016/S1470-2045(12)70246-2. Review.

PMID:
22846838
39.

Obesity and food insecurity at the same table: how head start programs respond.

Gooze RA, Hughes CC, Finkelstein DM, Whitaker RC.

Prev Chronic Dis. 2012;9:E132. Epub 2012 Jul 26.

40.

Breast cancer in Brazil: present status and future goals.

Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE.

Lancet Oncol. 2012 Mar;13(3):e95-e102. doi: 10.1016/S1470-2045(11)70323-0. Review.

PMID:
22381937
41.

The Family Health Promotion Project (FHPP): design and baseline data from a randomized trial to increase colonoscopy screening in high risk families.

Lowery JT, Marcus A, Kinney A, Bowen D, Finkelstein DM, Horick N, Garrett K, Haile R, Sandler R, Ahnen DJ.

Contemp Clin Trials. 2012 Mar;33(2):426-35. doi: 10.1016/j.cct.2011.11.005. Epub 2011 Nov 12.

42.

Web-browser encryption of personal health information.

Morse RE, Nadkarni P, Schoenfeld DA, Finkelstein DM.

BMC Med Inform Decis Mak. 2011 Nov 10;11:70. doi: 10.1186/1472-6947-11-70.

43.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

44.

Clinically relevant changes in family history of cancer over time.

Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C, Griffin CA, Moorman PG, Edwards KL, Hill DA, Berg JS, Tomlinson GE, Anton-Culver H, Strong LC, Kasten CH, Finkelstein DM, Plon SE.

JAMA. 2011 Jul 13;306(2):172-8. doi: 10.1001/jama.2011.955.

45.

A test for the relationship between a time-varying marker and both recovery and progression with missing data.

Schoenfeld DA, Rajicic N, Ficociello LH, Finkelstein DM.

Stat Med. 2011 Mar 30;30(7):718-24. doi: 10.1002/sim.4145. Epub 2011 Jan 11.

PMID:
21394748
46.

Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method.

Finkelstein DM, Schoenfeld DA.

J Clin Oncol. 2011 Mar 20;29(9):1093-5. doi: 10.1200/JCO.2010.33.9374. Epub 2011 Feb 14. No abstract available.

PMID:
21321297
47.

Identification and interpretation of longitudinal gene expression changes in trauma.

Rajicic N, Cuschieri J, Finkelstein DM, Miller-Graziano CL, Hayden D, Moldawer LL, Moore E, O'Keefe G, Pelik K, Warren HS, Schoenfeld DA; Inflammation and the Host Response to Injury Large Scale Collaborative Research Program.

PLoS One. 2010 Dec 20;5(12):e14380. doi: 10.1371/journal.pone.0014380.

48.

Reaching staff, parents, and community partners to prevent childhood obesity in Head Start, 2008.

Gooze RA, Hughes CC, Finkelstein DM, Whitaker RC.

Prev Chronic Dis. 2010 May;7(3):A54. Epub 2010 Apr 15.

49.

Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.

Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM.

Breast Cancer Res Treat. 2010 Nov;124(2):441-51. doi: 10.1007/s10549-010-0842-y. Epub 2010 Mar 23.

50.

Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer.

Nichols AC, Finkelstein DM, Faquin WC, Westra WH, Mroz EA, Kneuertz P, Begum S, Michaud WA, Busse PM, Clark JR, Rocco JW.

Clin Cancer Res. 2010 Apr 1;16(7):2138-46. doi: 10.1158/1078-0432.CCR-09-3185. Epub 2010 Mar 16.

Supplemental Content

Loading ...
Support Center